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Pax6 mutations cause complex ocular malformations, but it is uncertain whether early eye development normally requires Pax6 function in
both the optic vesicle (OV) and the lens epithelium, or only in the latter. To investigate this question, we electroporated the OV with anti-Pax6 or
control morpholinos before the onset of lens placode formation. Pax6 downregulation was already detectable in the OV 10 h after anti-Pax6
treatment, and was accompanied by a significant increase in the death of OV cells. A small eye-like phenotype developed thereafter, whose
severity was developmental stage-dependent. When treatment was applied at Hamburger Hamilton (HH) stage 10, there was no optic cup
formation, and lens development was abortive despite normal Pax6 expression in the lens epithelium. Treatment at HH stage 11 resulted in
structurally normal lens and optic cup, although the latter showed abnormal expression domains for several transcription factors. Early eye
development therefore requires cell-autonomous Pax6 function not only in the lens but also in the optic vesicle, where it plays a hitherto unknown
role in cell survival. The results, moreover, indicate that there is a critical stage during which Pax6 expression in the OV is necessary for normal
lens development.
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The vertebrate eye develops through a complex series of
morphogenetic events requiring the differentiation and coordi-
nated assembly of structures with different embryonic origin.
The initial eye primordium is the optic vesicle (OV), a neural
tube evagination surrounded by cephalic mesenchyme and
ectoderm. The optic vesicle invaginates and becomes patterned
into the optic stalk (OS), the retinal pigment epithelium (RPE)Abbreviations: afi, average fluorescence intensity; au, arbitrary units; α-
Pax6 embryos, embryos treated with Pax6-MP; C-MP, control morpholino; C-
MP embryos, embryos treated with C-MP; ED, embryonic day; HH,
Hamburger–Hamilton; MP, morpholino; OV, optic vesicle; Pax6-MP, morpho-
lino against Pax6; PBS, phosphate-buffered saline; RPE, retinal pigment
epithelium; St, stage.
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doi:10.1016/j.ydbio.2006.02.033and the neural retina (NR); the surface ectoderm originates the
lens and the external epithelium of the cornea and the
conjunctiva, and the mesenchyme forms the corneal and
conjunctival stroma, the choroid and the sclera. A transient
period of close contact between the optic vesicle and the
presumptive lens ectoderm, during which they exchange
inductive signals, is critical for normal eye development
(reviewed by Chow and Lang, 2001; Fitzpatrick and van
Heyningen, 2005).
Mutations in several genes can cause congenital ocular
abnormalities, through mechanisms that are still incompletely
understood (Ferda Percin et al., 2000; Glaser et al., 1994; Jordan
et al., 1992; Voronina et al., 2004; review: van Heyningen and
Williamson, 2002; Fitzpatrick and van Heyningen, 2005).
Among these genes is Pax6, whose heterozygous mutations
cause human aniridia and Peter's anomaly (Glaser et al., 1992;
Hanson et al., 1994; Jordan et al., 1992), and the small eye
phenotype in mice and rats (Hill et al., 1991; Matsuo et al.,
1993). Anophthalmia can result from either loss-of-function
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expression of the Pax6 gene, suggesting dosage-dependent
Pax6 effects (Schedl et al., 1996).
The elucidation of the mechanisms leading to the small eye
phenotype has been challenging due to the reciprocal inductive
interactions between the optic vesicle and the lens ectoderm,
and to the complex patterns of Pax6 expression in both
structures. Pax6 is initially expressed throughout the optic
vesicle, but it becomes subsequently restricted to the presump-
tive RPE and neural retina, and eventually to differentiating
ganglion, amacrine and horizontal cells (Walther and Gruss,
1991; Li et al., 1994; Grindley et al., 1995; Belecky-Adams et
al., 1997; review: Chow and Lang, 2001). Pax6 mRNA
expression is also extensive in the presumptive lens ectoderm,
but becomes subsequently restricted to the lens placode (Li et
al., 1994; Grindley et al., 1995; Chow and Lang, 2001). A still
unanswered question is whether normal eye development
requires cell autonomous Pax6 activity in both the optic vesicle
and the lens ectoderm, or in only one of them. Some notions that
have received extensive (but not universal) acceptance in this
regard are: (i) that the primary defect leading to the small eye
phenotype is the failure of the surface ectoderm to form a lens
placode, (ii) that lens development requires Pax6 activity in the
prospective lens ectoderm but not in the optic vesicle and (iii)
that Pax6 is not essential for optic vesicle formation, although it
does play a role in subsequent steps of retinogenesis (review:
Mathers and Jamrich, 2000; Ashery-Padan and Gruss, 2001;
Ogino and Yasuda, 2000; Lang, 2004). These notions are
supported by descriptive studies of the small eye mutation (Hill
et al., 1991; Hogan et al., 1986), by recombination experiments
with normal and mutant embryonic tissues (Fujiwara et al.,
1994), by comparative analysis of Pax6 mutants and Rx-
deficient mice (Zhang et al., 2000) and by cre-lox-based Pax6
inactivation in the lens ectoderm (Ashery-Padan et al., 2000).
Grindley et al. (1995), however, observed that early Sey/Sey
mouse optic vesicles are abnormally broad and fail to constrict
proximally, prior to the time of lens placode formation;
suggesting a requirement for Pax6 in neural ectoderm. In
addition, analysis of Pax6 chimeric mice suggested that Pax6 is
required in the OV for maintenance of contact with the
overlying lens epithelium, allowing subsequent inductive
interactions (Collinson et al., 2000). More recently, expression
of a dominant-negative version of Pax6 in developing chick
embryo OV led to the conclusion that Pax6 expression in neural
tissue plays an important role in lens development (Reza and
Yasuda, 2004a). Further experimentation with methods allow-
ing Pax6 inactivation with high temporal and spatial resolution
appears necessary for solving these discrepancies. The electro-
poration of antisense morpholino oligonucleotides has been
shown to be suitable for experiments of this type (Corey and
Abrams, 2001; Heasman, 2002; Kos et al., 2003).
In this study, we have used electroporation of anti-Pax6
morpholinos to investigate whether downregulation of Pax6 in
the optic vesicle has cell-autonomous effects on its develop-
ment, and can trigger a small eye-like phenotype even when
Pax6 is normally expressed in the lens. The treatment was
initiated at Hamilton–Hamburger (HH) stages 9–12, before theonset of lens placode formation (Kamachi et al., 1998; Reza and
Yasuda, 2004b). Pax6 downregulation was already detectable in
the OV 10 h after electroporation, when a significant increase in
cell death was also observed. When treated at HH stage 10, the
embryos developed a severe small eye-like phenotype, with
lack of optic cup formation; lens development was abortive,
despite normal Pax6 expression in the prospective lens
ectoderm. When electroporation was done 7 h later (at HH St
11), however, the lens developed fairly normally and the optic
cup was well formed, but had defects in dorso-ventral polarity
reflected in the abnormal expression patterns of several
transcription factors. Taken together, the results demonstrate
that Pax6 has cell-autonomous functions in optic vesicle
development, which include a hitherto unknown role in the
regulation of cell survival, and that normal lens development
requires Pax6 expression in the optic vesicle during a critical
time window.
Materials and methods
Experimental animals
White Leghorn chick embryos from B and E Eggs (York Spring, PA), staged
as in Hamburger and Hamilton (1951), were used.
Morpholino antisense oligonucleotides
Fluorescein-labeled morpholinos were obtained from GeneTools LLC
(Philomath, OR). Two Pax6 morpholino antisense oligonucleotides (Pax6-
MP) were designed to target sequences shared by the two chicken Pax6 isoforms
(Epstein et al., 1994); one morpholino encompassed the translation start codon
(5′CACGCCGCTGTGACTGTTCTGCATG3′), while another corresponded to
the 5′ untranslated region (5′CTCGCCTGGAGCGGTCTGGAAGCCG3′). A
standard control morpholino (C-MP) provided by GeneTools was used as a
negative control; BLAST analysis showed that it had no target sequences in the
chicken genome.
In ovo electroporation
Embryonic day (ED) 2 chick embryos were windowed as described (Selleck,
1996). Under blue light illumination generated with a blue dichroic filter
(Edmund Industrial Optics, Barrington, NJ) attached to a fiber optic lamp,
morpholino solution (0.4–0.6 μl, 1 mM in sterile 1× PBS) was injected in the
forebrain ventricular cavity of HH St 9–12 embryos with a Harvard Apparatus
PLI-100 picoinjection system using glass capillary needles. Electroporation was
performed immediately after injection as in Nakamura and Funahashi (2001),
with some modifications. In brief, platinum-iridium electrodes (FHC Inc,
Bowdoinham, ME) were positioned at each side of the embryo head; the [−]
electrode was consistently placed adjacent to the left optic vesicle, and the anode
next to the right optic vesicle. The distance between electrodes was ca. 1.5 mm.
Five square pulses (18 V, 50 ms length, 950 ms interval) were delivered using an
ECM 830 electroporator (BTX, Holliston, MA). A digital multimeter (Multi-
master 560, Extech Instruments, Waltham, MA) connected to a resistor (1.0Ω
1%) was inserted between the electroporator and the electrodes to monitor the
peak current (40–80 mA) through the embryo head during electroporation. After
electroporation, 10 μl of sterile PBS was dispensed over the embryo head,
windows were closed with transpore tape and the embryos were returned to the
incubator.
Immunohistochemistry
Embryos were fixed in 4% paraformaldehyde in PBS for 2–4 h at room
temperature, embedded and frozen for cryosectioning as in Barthel and
Raymond (1990). Immunohistochemistry was carried out in 10 μm sections as
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sections were incubated at 4°C overnight with a 1:50 dilution of a mouse
monoclonal antibody that recognizes both chicken Pax6 isoforms (Kawakami et
al., 1997; Nishina et al., 1999), obtained from the NICHD-funded Develop-
mental Studies Hybridoma Bank maintained by The University of Iowa (Iowa
City, IA); in some cases, rabbit polyclonal antibodies against Pax2 (Covance;
Berkeley, CA) or L-Maf (kindly provided by K. Yasuda; Ogino and Yasuda,
1998) were simultaneously added at 1:100 and 1:1000, respectively. Antibody
binding was routinely detected with Alexa 594 goat anti-mouse and Alexa 488
goat anti-rabbit (Molecular Probes, OR); Alexa 546 goat anti-mouse and Alexa
647 goat anti-rabbit were used for verification of Pax2 and Pax6 colocalization
by confocal microscopy with an LSM 510 Meta (Zeiss; Thornwood, NY). MP-
associated fluorescein was thoroughly bleached by exposure to UV light when it
could interfere with particular combinations of secondary antibodies. For
analysis at or after stages 17–18, MP-associated fluorescence was amplified
using a goat antibody against fluorescein (Molecular Probes, OR), detected
either with an Alexa 488 rabbit anti-goat antibody or with the Tyramide
amplification system according to manufacturer's instructions (TSA-PLUS
Fluorescein System; Perkin Elmer, Boston, MA).
In situ hybridization
In situ hybridization was carried out according to Belecky-Adams et al.
(1997). Probes were generated from cDNAs generously provided by the
following investigators: Chx10 (Olof Sundin, Johns Hopkins University,
Baltimore, MD); cVax (Constance Cepko, Harvard Medical School, Boston,
MA); cTbx5 (Katherine Yutzey, Children's Hospital Medical Center, Cincinnati,
OH); cMitf (Makoto Mochii, National Institute for Basic Biology, Okazaki,
Japan). A probe for cRaxL was generated by PCR amplification of a 227-bp
segment from embryonic chick retina cDNA using AGATTCTCCC-
GAGCCTTCGC and GGTCCCCCTCACACTTATTG as forward and reverse
primers, respectively. Probes were labeled with digoxigenin RNA labeling mix,
and hybridization was detected with an alkaline phosphatase-labeled anti-
digoxigenin antibody and the NBT/BCIP alkaline phosphatase enzymatic
reaction (Roche; Indianapolis, IN).
Embryonic analysis immediately after electroporation
MP fluorescence was first examined in embryos in toto (n = 22) using low
magnification objectives in a Zeiss fluorescence microscope, and documented
photographically in dorsal, ventral, frontal and sagital views. For quantitative
analysis, 6 μm sections were photographed under fluorescence illumination and
processed for image analysis using ImageJ (NIH). Five embryos from each
experimental group were analyzed in triplicate sections. In each section, the area
of the optic vesicle neuroepithelium showing MP-associated fluorescence and
the area of the entire optic vesicle neuroepithelium were measured, and their
ratio (MP[+] area/optic vesicle area) was expressed in arbitrary units (au). The
average fluorescence intensity (afi) of the MP[+] territory was calculated as
mean fluorescent intensity in au/MP[+] area in μm2.
Quantitation of Pax6 immunofluorescence
Analysis was done in 6 μm sections from embryos electroporated with C-
MP or Pax6-MP at stages 10 or 11, fixed 10 h after treatment. Comparisons
involved equivalent regions of the optic vesicle neuroepithelium from embryos
at identical HH stages. Every third section from each OV (3–4 sections/embryo;
n = 6 embryos/experimental group) was processed for Pax6 immunofluores-
cence and photographed for MP-associated fluorescence in the green channel
and for Pax6 immunofluorescence in the red channel. Image analysis with
ImageJ was used to calculate the afi of Pax6 immunofluorescence in the MP[+]
area of the OV (mean Pax6 immunofluorescence intensity in au/MP[+] area
in μm2).
DNA Nick End labeling by the TUNEL technique
Every third 6-μm section (4–7 sections/embryo; n = 5–7 embryos/
experimental group) was processed by the TUNEL technique as described inPortera-Cailliau et al. (1994), modified for fluorescent detection using
biotinylated 16-dUTP followed by incubation with Rhodamine Avidine D
(1:100, Vector, Burlingame, CA) for 30 min at RT. Sections were photographed
in the red channel for TUNEL[+] cells and the green channel for MP-associated
fluorescence. Quantitation was done using ImageJ and results are expressed as
TUNEL[+] cells/MP[+] area in mm2.
Cell proliferation
Every third 6-μm section (4–7 sections/embryo; n = 5–7 embryos per
experimental group) was processed by immunohistochemistry with a polyclonal
antibody against Phospho-Histone H3 (PH3; Cell Signaling, Beverly, MA),
which recognizes cells in G2 phase and metaphase (Zhang and Yang, 2001a and
references therein), followed by Alexa 594 goat anti-rabbit antibody. Sections
were analyzed as described for TUNEL quantification, and results expressed as
PH3[+]/MP[+] cells/unit of MP[+] area in mm2.
Statistical analysis
Statistical significance was calculated with the t test or two-way ANOVA for
independent samples (Lowry, 2001). Results are expressed as “mean ± standard
error of the mean”.
Results
Antisense morpholino incorporation into optic vesicle cells
Although electroporated morpholinos were initially thought
to move towards the anode, as highly charged DNA
molecules do (Kos et al., 2003), this assumption has been
questioned because morpholinos are electrically neutral, and
acquire a single [−] charge when conjugated to carboxy-
fluorescein (Kos et al., 2003; Summerton and Weller, 1997).
We therefore investigated the directionality, extent and
reproducibility of morpholino incorporation in a series of
experiments in which groups of chick embryos at HH stages
9–12 were injected into the forebrain ventricular cavity with
fluorescein-labeled C-MP or Pax6-MP, electroporated and
fixed immediately (time zero, T0). Unexpectedly, MP
fluorescence was always observed predominantly in the left
optic vesicle, adjacent to the cathode (negative) electrode
(Figs. 1A, C–J). Some fluorescence was occasionally
observed also in the ipsilateral side of the neural tube, as
well as in the contralateral optic vesicle and ectoderm (Figs.
1E, H). This pattern of morpholino incorporation (considered
further in Discussion) precluded comparisons between
“treated” and “control” optic vesicles within one embryo;
the study was therefore designed as a comparison between the
left optic vesicle of embryos treated with either Pax6-MP or
C-MP (referred to henceforth as “α-Pax6 embryos” and “C-
MP embryos”, respectively).
Morpholino incorporation was compared in more detail in
embryos electroporated at stages 10 and 11 which, as
described below, showed extensive differences in their
responses to Pax6-MP. Embryos from two independent
experiments (n = 22) were first examined at low magnifi-
cation with ultraviolet illumination; regardless of stage at
treatment, C-MP and Pax6-MP fluorescence was consistently
observed in the distal-most part of the optic vesicle, adjacent
to the ectoderm (Figs. 1C–H). Similar patterns were also
Fig. 1. Morpholino oligonucleotide electroporation into optic vesicle cells in ovo. (A) Schematic diagram of injection and electroporation at HH St 9–12.
Morpholino solutions were injected into the prosencephalic ventricular cavity; the [−] electrode was placed near the left optic vesicle (lov) and the [+] electrode
near the right optic vesicle (rov). Distance between electrodes was ca. 1.5 mm. (B) Section planes used in this study differed as the embryonic curvatures changed
during development. (a–a′) “Frontal” sections of embryos fixed either immediately or 10 h after electroporation; (b–b′) “frontal” and (c–c′) “transversal” sections
of embryos fixed at HH St 17–18 or at ED5. (C–H) Dorsal view of whole mounts (C, D, F, G) and frontal sections (E, H) of embryos electroporated with control
morpholinos (C-MP) or anti-Pax6 morpholino (Pax6-MP) at HH St 10 or HH St 11, analyzed immediately after treatment (T0). MP-associated fluorescence (green)
was always observed predominantly in the distal-most part of the optic vesicle (arrows); some MP fluorescence was occasionally seen also in the ipsilateral neural
tube (open arrowheads) and in the contralateral optic vesicle and ectoderm (filled arrowheads). (I–J) Dorsal view comparison of morpholino incorporation patterns
in embryos fixed immediately after electroporation at HH St 11 (J) with respect to embryos electroporated at HH St 10, and fixed 5 h later when they reached HH
St 11 (I; arrow indicates green morpholino fluorescence). Scale bars: 100 μm.
122 M.V. Canto-Soler, R. Adler / Developmental Biology 294 (2006) 119–132observed in embryos treated at HH St 9 or 12 (not shown).
Image analysis in frontal sections (see Fig. 1B, a–a′) showed
no significant differences in the area and afi of the MP[+]
territories between α-Pax6 and C-MP embryos, or between
embryos treated with Pax6-MP at stages 10 or 11 (Table 1).
Fluorescent territories also appeared qualitatively and
quantitatively similar when embryos fixed immediately
after electroporation at HH St 11 were compared with
embryos electroporated at HH St 10 and fixed 5–7 h later,when they reached HH St 11 (Figs. 1I, J, and data not
shown).
Temporal aspects of Pax6 downregulation by Pax6-MP
Effects of Pax6-MP and C-MP on Pax6 expression were
evaluated immunocytochemically with Pax6 antibodies. Twen-
ty-four hours after electroporation, Pax6 immunofluorescence
was practically undetectable in MP[+] regions of α-Pax6
Table 1
Quantitative analysis of morpholino incorporation
Stage at
treatment
onset
Morpholino
treatment
MP[+] area of the
optic vesicle (au)
MP average
fluorescence intensity
(au/μm2)
HH St 10 control 0.55 ± 0.01 0.017 ± 0.002
anti-Pax6 0.52 ± 0.06 0.018 ± 0.002
HH St 11 control 0.54 ± 0.03 0.021 ± 0.002
anti-Pax6 0.45 ± 0.04 0.02 ± 0.002
Quantitative image analysis of embryos electroporated with control or anti-Pax6
morpholino at HH stages 10 or 11. Three sections per embryo (5 embryos/
experimental group) were analyzed; results are expressed as “mean ± standard
error of the mean”. No significant differences in the area and average
fluorescence intensity of the morpholino [+] territory of the optic vesicles were
observed (P > 0.05). au, arbitrary units.
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that of untreated embryos (Figs. 2A, B, and data not shown).
Pax6 downregulation could already be detected qualitatively
10 h after treatment, and quantitative image analysis showed
that Pax6 immunofluorescence intensity was 40–50% lower in
MP[+] regions of optic vesicles treated with Pax6-MP than in
their C-MP counterparts, independently of the embryonic stage
at treatment onset (Figs. 2C–E). Pax6 expression in the surface
ectoderm (Figs. 2C, D) and the developing lens (Figs. 2A, B)
was normal in all cases, as expected from the absence of MP
incorporation in the surface ectoderm.Fig. 2. Pax6 became undetectable approximately 24 h after Pax6-morpholino incorp
sections of embryos treated with control morpholino (A, C-MP) or anti-Pax6 morphol
processed for double-labeling immunofluorescence for Pax6 (red) and MP (green). P
epithelium (rpe), the ectoderm (ec) and the lens (le), but was essentially undetectable in
Frontal sections of embryos electroporated at HH St 10 with control morpholino (C
immunodetection (red signal); green signal corresponds to MP-associated fluoresc
neuroepithelium (ovn) of embryos treatedwith Pax6-MP (D). The nature of the bodies
dependent changes in cell death and Figs. 6A–H. Scale bars: A and B: 50 μm; C and
vesicle of embryos treated as in panels C and D. Average fluorescence intensity (afi), c
treated with anti-Pax6 morpholinos (Pax6-MP) than in their control counterparts (C-Pax6-MP treatment induced small eye-like phenotypes in a
stage-dependent manner
Eye development was normal in C-MP embryos at all the
stages studied, but α-Pax6 embryos developed small eye-like
phenotypes in a stage-dependent manner (Fig. 3; sections as in
Fig. 1B, c–c′). Pax6-MP treatment at HH St 9–10 led to lack of
optic cup formation, with the optic vesicle developing instead
into a rudimentary, pigmented, club-shaped hollow structure
(Fig. 3B). Pax6-MP treatment at HH St 11–12 did not prevent
the development of an optic cup (Fig. 3D), resulting in a less
severe phenotype; the optic cup, however, did show some
abnormalities in the neural retina and optic stalk (see below).
Lens development was also affected in a stage-dependent
manner; thus, a rudimentary lens vesicle was seen in embryos
treated at HH St 9–10, but a morphologically normal lens
developed in embryos treated at HH St 11–12. These stage-
dependent phenotypic differences were consistently observed in
six independent experiments, with two different Pax6
morpholinos.
Treatment with Pax6-MP at stages 9 or 10 induced a severe
small eye-like phenotype
Analysis on ED5. C-MP and α-Pax6 embryos were analyzed
first on ED5 (HH stages 26–27) when optic cup derivatives andoration, and its downregulation was detectable even earlier. (A and B) Frontal
ino (B, Pax6-MP) at HH St 11, harvested 24 h after treatment (HH St 17–18) and
ax6 immunofluorescence remained similar in both cases in the retinal pigment
the dorsal region of the retina that contains anti-Pax6morpholino (B, dnr). (C, D)
) or anti-Pax6 morpholino (D), fixed 10 h later and processed for Pax6 protein
ence. Pax6 immunofluorescence intensity appeared lower in the optic vesicle
showing intensemorpholino fluorescence in panels B andC is discussed in Stage-
D: 25 μm. (E) Quantification of Pax6 immunofluorescence intensity in the optic
alculated as explained in Materials and methods, was 40–50% lower in embryos
MP), regardless of the stage of treatment (*P < 0.01).
Fig. 3. Stage-dependency of the small-eye like phenotypes induced by Pax6-MP
treatment. (A–D) Transversal sections (Figs. 1B, c–c′) of ED5 embryos treated
with control morpholino (C-MP) or anti-Pax6 morpholino (Pax6-MP) at HH
stages 10 (A, B) or 11 (C, D). Embryos treated with C-MP appeared normal at all
the stages studied (A, C). Embryos treated with Pax6-MP at HH St 10 (B)
showed a rudimentary vesicle, delimited by a thin-pigmented epithelium,
instead of an optic cup; rl: rudimentary lens. Embryos treated with Pax6-MP at
HH St 11 (D) developed optic cups that, although somewhat smaller than
normal, had distinct neural retina (nr) and retinal pigment epithelium (rpe)
domains, and were accompanied by a normal lens (le). The optic fissure
remained opened in these eyes (D, arrowhead). Scale bar: 400 μm.
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embryos (Table 2 and Figs. 4A–F). Eighty-five percent of left
eyes appeared smaller in α-Pax6 than in C-MP embryos (Table
2) or in untreated embryos (not shown). More than half of the
left eyes in α-Pax6 embryos appeared darkly pigmented, and
showed an incompletely closed optic fissure (Table 2 and Fig.Table 2
Pax6-MP treatment induced small eye like phenotypes in a stage-dependent manner
Stage at
treatment
onset
Time of
analysis
Morpholino
treatment
n
HH St 9–10 ED5 Control 8
anti-Pax6 13
HHSt 17–18 Control 19
anti-Pax6 20
HH St 11–12 ED5 Control 11
anti-Pax6 14
HH St 17–18 Control 20
anti-Pax6 29
Embryos were electroporated with either control or anti-Pax6 morpholino at HH stage
until ED5. Results correspond to observations from six independent experiments wi4G). This rudimentary vesicle appeared in frontal sections (see
Fig. 1A, b–b′) as a club-shaped cavity delimited by a simple
pigmented epithelium, with no signs of optic cup invagination
(Figs. 4I, J). The epithelium appeared unpigmented and thick in
the ventral region of the vesicle, protruding into its cavity in
some cases (Figs. 4I, J). The lens phenotype will be described
below (Section V).
The expression patterns of several transcription factors in
ED5 C-MP embryos were similar to those described for
untreated embryos. Thus, Pax6 showed a typical periphery-high
to fundus-low gradient of expression (Fig. 4B), whereas Pax2,
known to be excluded from Pax6[+] domains (Schwarz et al.,
2000), appeared restricted to the optic stalk and to a Pax6[−]
region of the ventral retina (Fig. 4B). Chx10 and Rax/Rx signals
appeared fairly evenly distributed in the neural retina (Figs. 4E,
F). In α-Pax6 embryos, on the other hand, Pax6 expression was
strong in the pigmented epithelium surrounding the vesicle but
much lower in the ventral thick epithelium, with the exception
of some Pax6[+] cells that were occasionally seen in this region
(Fig. 4H and inset). Chx10 and Rax/Rx were undetectable in the
thin wall of the vesicle, although its heavy pigmentation may
have masked hybridization signals; these factors, on the other
hand, were present in the thick neuroepithelial protrusion
projecting into the cavity of some vesicles (Figs. 4I, J).
Analysis at stage 17–18. Earlier stages were analyzed to gain
additional insights into the mechanisms leading to the
phenotypic abnormalities observed on ED5. Embryos treated
at HH St 10 were fixed 25–30 h later, when they reached St 17–
18. Whole mount analysis showed that the transformation of the
optic vesicle into an optic cup was completed in 100% of the C-
MP embryos, but in only 20% of the α-Pax6 embryos (Table 2).
In the remaining 80% of the embryos, the optic vesicle had
failed to invaginate, remaining as a rudimentary vesicle, and the
lens was underdeveloped or absent (Table 2). In whole mounts,
morpholino fluorescence was readily detectable in the dorsal
region of the eye in C-MP embryos (Fig. 5A), and in the
rudimentary vesicle in α-Pax6 embryos (Fig. 5H). In frontal
sections (see Fig. 1B, b–b′), C-MP embryos showed a normal
optic cup, with well-defined neural retina, pigmented epitheli-
um, optic stalk and lens (Figs. 5B–G). On the other hand, α-Normal
optic
cup
(%)
Smaller
optic
cup
(%)
Rudimentary vesicle
Rudimentary
lens (%)
No lens
structure
100 0 0 0
15 31 54 0
100 0 0 0
10 10 65 15
91 9 0 0
70 30 0 0
100 0 0 0
48 45 7 0
s 9–12, and allowed to develop for 25–30 h (when they reached HH St 17–18) or
th two different anti-Pax6 morpholino.
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this stage, and its replacement by a vesicle, with a central cavity
surrounded by a thin epithelium with no identifiable neural
retina domain (Figs. 5I–L).
In C-MP embryos, Pax6 immunoreactivity was detectable in
the lens, was evenly distributed in the RPE domain and showed a
periphery-high to fundus-low gradient in neural retina (Fig. 5B).
In α-Pax6 embryos, on the other hand, Pax6 immunoreactivitywas strong in the lens vesicle and in the dorsal-most region of the
rudimentary optic vesicle (Fig. 5I); lack of Pax6 signal in the rest
of the vesicle was accompanied by a broad Pax2 expression
domain (Fig. 5I). As reported for untreated embryos (Chen and
Cepko, 2000; Mathers et al., 1997; Ohuchi et al., 1999), Chx10
and Rax/Rx were confined to the neural retina domain in C-MP
embryos (Figs. 5E, F), but were undetectable in 8/10 Pax6-MP-
treated eyes (Figs. 5J, K), and observed only in a small area in
the remaining 2 embryos (not shown). Mitf (which could not be
analyzed on ED5 due to the presence of pigment granules in the
RPE) was restricted at HH stage 17–18 to the RPE domain in C-
MP embryos (Fig. 5G) as described for untreated embryos
(Mochii et al., 1998), but appeared expanded in α-Pax6 embryos
(Fig. 5L). Taken together, these results suggest a change in cell
fate from neural retina toward RPE.
Treatment with Pax6-MP at stages 11 or 12 led to a milder
small eye-like phenotype
Analysis at ED5. In contrast to the phenotype of α-Pax6
embryos treated at HH stages 9 or 10, Pax6-MP treatment at
stage 11–12 did not prevent invagination of the optic vesicle into
an optic cup containing well defined neural retina, RPE and optic
stalk domains (Table 2 and Figs. 4K–P). These optic cups,
however, consistently showed lack of closure of the optic fissure
(“coloboma”; see Fig. 5K), and were smaller than normal in 4
(30%) of the embryos (Table 2 and Fig. 5K). Analysis in frontal
sections (see Fig. 1B, b–b′) showed a mesenchyme-like tissue
occupying the position of the missing retina in the colobomatous
ventral region (not shown). Pax6 expression was reduced in the
ventral retina of α-Pax6 embryos, with concomitant expansion
of the Pax2 domain (Fig. 4L). Vax and Tbx5 are transcription
factors involved in dorso-ventral retina patterning (Leconte et
al., 2004; Schulte et al., 1999). Vax appeared restricted to optic
stalk and ventral retina in C-MP-treated (Fig. 4C) and untreated
embryos (not shown), but in α-Pax6 embryos, it was present not
only there but also in the dorsal neural retina (Fig. 4M); the latter,Fig. 4. ED5 embryos treated with C-MP or Pax6-MP at HH St 10 or 11. (A, G,
K) Left side view of whole-mounted heads; (B–P) frontal sections (Figs. 1B, b–
b′) of the embryonic left eye. (A–F) Embryos treated with control morpholino
(C-MP) at either St 10 or 11 showed a similarly normal phenotype. (G–J)
Embryos treated with anti-Pax6 morpholino (Pax6-MP) at HH St 10. (G) Note
the presence of a darkly pigmented rudimentary eye structure with an open optic
fissure (arrowhead). (H–J) Pax6 (H, red) was strongly expressed in the
pigmented epithelium of the vesicle (filled arrowhead), as well as in the
rudimentary lens (rl) and the ectoderm (ec); a thick ventral epithelial mass
protruding into the vesicular lumen was positive for Pax2 (H, green), and only
showed scattered Pax6 (+) cells (H, inset). That same ventral mass also showed
ISH signals for Chx10 (I) and Rax/Rx (J; open arrowheads, and insets). (K–P)
Embryos treated with Pax6-MP at HH St 11. (K) The external appearance of the
eye was relatively normal, although it appeared smaller than in controls and
showed an open optic fissure (arrowhead). (L) Downregulation of Pax6 (red) in
the ventral retina was accompanied by expansion of the Pax2 domain (green).
(M–N) Comparison with panels C and D shows ectopic expression of Vax in
dorsal retina domain (M, filled arrows, and inset), with concomitant lack of
Tbx5 expression (N, open arrow, and inset). (O–P) Chx10 and Rax/Rx
expression patterns were similar to controls (E, F). nr: neural retina; rpe: retinal
pigment epithelium. Scale bars: 200 μm except for panels A, G and K: 400 μm.
126 M.V. Canto-Soler, R. Adler / Developmental Biology 294 (2006) 119–132in turn, lacked Tbx5 signal normally seen in C-MP embryos
(Figs. 4D, N). Chx10 and Rax/Rx appeared normally distributed
in α-Pax6 embryos (Figs. 4O, P).
Analysis at stages 17–18. Twenty-seven of the 29 α-Pax6
embryos studied at St 17–18 had an anatomically normal left
eye which, however, was smaller than in C-MP embryos in 13
(45%) of the cases (Table 2). The dorsal neural retina showed
equivalent MP fluorescence in C-MP and α-Pax6 embryos
(Figs. 5A, M), but in the latter it appeared thinner, was separated
from the retinal pigment epithelium and showed abnormalities
in Pax6, Pax2, Vax and Tbx5 expression (Figs. 5N–P)
resembling those described in the preceding section for ED5
embryos. Chx10 and Rax/Rx expression domains appeared
normal (Figs. 5Q, R).
Pax6-MP treatment increased cell death but did not affect cell
proliferation
Changes in cell survival and/or proliferation could conceiv-
ably contribute to the abnormal phenotypes observed in α-Pax6
embryos, and were therefore investigated in embryos electro-
porated at HH St 10 or 11.
Stage-dependent changes in cell death
Round bodies, reminiscent of pyknotic cells, appeared more
abundant in the MP[+] region of α-Pax6 embryos treated at
stages 10 or 11 (Fig. 6A) than in their C-MP counterparts (Fig.
6E). These bodies showed intense DAPI fluorescence (Fig. 6B)
and MP fluorescence (Fig. 6C), and were TUNEL[+] (Fig. 6D).
Ten hours after electroporation, increases in TUNEL[+] cells in
α-Pax6 embryos with respect to C-MP embryos wereFig. 5. Embryos treated with C-MP or Pax6-MP at HH St 10 or 11, analyzed at
HH stage 17–18. (A, H, M) Merged image of the bright field and fluorescence
images of the left side view of whole-mounted heads; the arrowheads indicate
MP-associated fluorescence (green). (B–R) Frontal sections (Figs. 1B, b–b′) of
the embryonic left eye. (A–G) Embryos treated with control morpholino (C-MP)
at either St 10 or 11 showed a similarly normal phenotype. (H–L) Embryos
treated with anti-Pax6 MP (Pax6-MP) at HH stage 10. (H) External inspection
showed a very small vesicular structure instead of an eye; morpholino
fluorescence appeared to occupy most of the vesicle (arrowhead). (I) Pax6
(red) was strongly expressed in the ectoderm (ec) and the rudimentary lens (rl)
but was only detectable in the dorsal-most region of the rudimentary optic
vesicle (filled arrowhead); Pax2 (green) was broadly expressed in the rest of the
vesicle (open arrowhead). (J–K) Chx10 and Rax/Rx were undetectable in the
rudimentary vesicle. (L) Mitf was expressed in the entire vesicle epithelium
(arrowhead). (M–R) Embryos treated with Pax6-MP at HH St 11. (M) External
appearance; the optic cup appeared generally similar to, but somewhat smaller
than in controls (A); their respective patterns of morpholino distribution were
also similar (arrowheads in panels A and M). (O–P) In transversal sections, the
dorsal neural retina (nr) appeared separated from the retinal pigment epithelium
(rpe) (compare with insets in panels C and D). (N) Pax6 (red) appeared strongly
positive in the lens (le) and ectoderm (ec), but was almost undetectable in the
dorsal retina domain (arrowhead). Pax2 (green) was ectopically expressed in that
region. (O) The Vax[+] domain expanded from its normal location (filled arrow)
towards the dorsal retina (open arrows; compare with panel C). (P) Tbx5
expression became undetectable in these eyes (open arrow, compare with panel
D). (Q–R) Chx10 and Rax/Rx were normally expressed in the neural retina.
Scale bar: 100 μm except for A, H and M: 300 μm.
Fig. 6. Analysis of cell death and cell proliferation 10 h after morpholino treatment. (A–H) High magnification images of the optic vesicle neuroepithelium from
embryos treated with control morpholino (C-MP) or anti-Pax6 morpholino (Pax6-MP). (A–C) Numerous rounded bodies, resembling pyknotic cells (arrowheads)
could be observed with Nomarski optics (A), they appeared intensely fluorescent with DAPI (B), and also showed strong morpholino fluorescence (C). (D) These
pyknotic bodies were TUNEL[+] (red), and appeared particularly abundant in morpholino-rich areas of the retina (green). (E–H) Equivalent sections from an embryo
treated with C-MP, in which pyknotic bodies were rarely seen. (I–L) Low magnification images of frontal sections (see Figs. 1B, a–a′) of the head of embryos treated
with C-MP (I, K) or Pax6-MP (J, L) at HH stages 10 (I, J) or 11 (K, L), processed for the TUNEL technique. The sections are oriented dorsal-side up, TUNEL[+] cells
are in red and MP-associated fluorescence in green. The left optic vesicles (arrows) showed similar morpholino fluorescence in all cases, but TUNEL (+) cells were
only conspicuous in embryos treated with Pax6-MP (J, L), and appeared more abundant when the embryos were treated at St 10 (J) than at St 11 (L). Quantitative
analysis is shown in Table 3. TUNEL (+) cells were seldom seen in the right optic vesicles (arrowheads). Asterisk indicates an area of normal cell death in the ventral
region of the neural tube. (I′–L′) High magnification images of the left optic vesicle of the embryos showed in panels I–L. (M–P) High magnification images of
equivalent regions of the optic vesicle of embryos treated as in panels I–L and immunolabeled for PH3 protein detection. No differences in the number of PH3[+] cells
(arrowheads) were seen between embryos treated with Pax6-MP and their control counterparts (see also Table 3). Scale bars: 25 μm, except for I–L: 100 μm.
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was at St 10 (Table 3 and Figs. 6I–J) or 11 (Table 3 and Figs.
6K–L). On the other hand, TUNEL[+] cells were significantly
more abundant in α-Pax6 embryos treated at St 10 than in those
treated at St 11 (Table 3 and Figs. 6J,L).
To control for possible non-specific effects of morpholinos
on cell death, we also quantitated TUNEL[+] cells in a region
of the embryonic neural tube where morpholinos becameincorporated during electroporation. Although MP[+] fluores-
cence in that region of the neural tube (0.0039 ± 0.0005 au)
was similar to that seen in the optic vesicle (0.0049 ±
0.0005 au; P > 0.05), no significant differences in the
frequency of TUNEL[+] cells in the neural tube were found
between C-MP and α-Pax6 embryos (310 ± 48 and 438 ± 97
cells/mm2 respectively, P > 0.05). These results suggest that
increases in cell death in the optic vesicle of α-Pax6 embryos
Table 3
Quantification of TUNEL[+] and PH3[+] cells 10 h after morpholino
electroporation
Stage at treatment
onset
Morpholino
treatment
TUNEL[+] cells/MP
[+] area
PH3[+] cells/MP
[+] area
HH St 10 Control 587 ± 117a 406 ± 26
anti-Pax6 2818 ± 526b 481 ± 52
HH St 11 Control 746 ± 78c 575 ± 120
anti-Pax6 1666 ± 332d 674 ± 131
Quantitation was done in 4–7 sections/embryo (n = 5–7 embryos/experimental
group). Values are expressed as “mean ± standard error of the mean”. TUNEL[+]
cells were significantly higher in embryos treated with anti-Pax6 morpholino
than those treated with control morpholino at either HH stage 10 (a,bP < 0.01) or
HH stage 11 (c,dP < 0.01). In addition, embryos treated with anti-Pax6
morpholino at HH St 10 had significantly more TUNEL[+] cells than those
treated with anti-Pax6 morpholinos at HH St 11 (b,dP < 0.05). No significant
differences were seen in proliferating PH3[+] cells.
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morpholinos.
Cell proliferation was not affected by Pax6-MP
Cell proliferation was quantitated by immunocytochemistry
with an antibody against phosphohistone-3 (PH3) (see Materi-
als and methods). Ten hours after electroporation, when changes
in cell death were already prominent, we saw no significant
differences in PH3[+] cells between embryos treated with Pax6-
MP or C-MP at either stage (Table 3 and Figs. 6M–P), or
between embryos treated with Pax6-MP at HH stages 10 or 11
(Table 3 and Figs. 6N, P).
Optic vesicle treatment with Pax6-MP caused lens
abnormalities in a stage-dependent manner
Electroporation of C-MP in OV cells did not affect lens
development at any of the stages studied. Pax6-MP electro-Fig. 7. Stage-dependent developmental abnormalities of the lens after electroporation
through the lens of ED5 embryos treated with control morpholino (B) or anti-Pax6 mo
immunofluorescence for Pax6 (red) and L-Maf (green). Pax6 immunofluorescence wa
the treatment. When compared with controls (B), embryos treated with Pax6-MP
epithelium had ectopic Pax6 expression and lacked L-Maf immunoreactivity. On th
morphologically normal lens (le), in which domains of Pax6 and L-Maf immunorea
immunofluorescence was also detected in the ectoderm (ec) in all the cases. (nr) neur
panel A is shown at higher magnification than panels B and C (scale bar: 100 μm iporation into OV cells at HH stages 9–10, on the other hand,
caused abortive lens development (compare Figs. 3A and B).
The rudimentary lens of Pax6 MP-treated eyes showed bright
Pax6 immunofluorescence, but did not show immunoreactivity
for L-Maf (Figs. 7A, B), a transcription factor important for lens
development (Ogino and Yasuda, 1998; Reza et al., 2002).
When OV cells were electroporated with Pax6-MP at HH stages
11–12, the eyes showed morphologically normal (although
occasionally smaller) lenses (Figs. 3C–D), whose L-Maf
immunoreactivity was indistinguishable from their C-MP
counterparts (Fig. 7C).
Discussion
In this study, we have used a loss-of-function approach,
based on the electroporation of fluorescein-labeled antisense
morpholino oligonucleotides or their corresponding controls, to
investigate whether Pax6 downregulation in the optic vesicle
has cell-autonomous effects on its development and can trigger
a small eye-like phenotype even when Pax6 is normally
expressed in the lens. The treatment was initiated at HH St 9–
12, before the onset of lens placode formation (Kamachi et al.,
1998; review: Reza and Yasuda, 2004b). The results can be
summarized as follows: (1) treatment with C-MP did not have
detectable effects on eye development; (2) at all the stages
studied, Pax6-MP caused downregulation of Pax6 immunoflu-
orescence, accompanied by changes in the expression domains
of other transcription factors relevant to eye development; (3)
Pax6 downregulation in MP[+] OV domains was already
detectable 10 h after electroporation, and was accompanied by a
significant increase in cell death; (4) although the area and
fluorescent intensity of MP[+] OV territories were similar in
embryos treated at HH St 10 or 11, increases in cell death were
more pronounced when treatment was applied on or before HHof Pax6-MP into the optic vesicle. (A–C) Transversal sections (Figs. 1B, c–c′)
rpholino (A, C) at HH stage 10 (A) or 11 (C), and processed for double-labeling
s detected in the lens in all cases, independently of the nature and time of onset of
at HH stage 10 (A) showed a rudimentary lens structure (rl), whose posterior
e other hand, embryos treated with Pax6-MP at HH stage 11 (C) developed a
ctivity were similar to those in controls lenses in location and brightness. Pax6
al retinal; (pe) pigmented epithelium of the rudimentary optic vesicle. Note that
n all cases).
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treated at HH stage 10, despite normal Pax6 expression in the
prospective lens ectoderm; (6) These embryos developed severe
small eye-like phenotype, with lack of optic cup formation; (7)
when electroporation was done 7 h later (at HH St 11), the lens
developed normally and the eye had an invaginated optic cup,
although the latter showed defects in dorso-ventral distribution
of several transcription factors.
The interpretation of morpholino-based experiments requires
careful evaluation of their possible toxicity, and of the
reproducibility and specificity of their effects. In our experi-
ments, fluorescein-conjugated morpholinos were injected into
the lumen of the prosencephalic vesicle, which was still in
continuity with the lumen of the evaginating optic vesicles.
Somewhat surprisingly, after electroporation morpholino fluo-
rescence was localized predominantly to cells of the left optic
vesicle (adjacent to the cathode); this may result from current-
induced opening of cell membrane pores, through which neutral
molecules can move by diffusion (Vanbever et al., 1998, and
reviewed by Denet et al., 2004). Although in principle this
could make the directionality of their incorporation less
predictable, it was reassuring that morpholino fluorescence
distribution was consistent and reproducible in our experiments.
Comparison of C-MP embryos with untreated controls, or with
embryos electroporated in the absence of morpholinos, did not
show detectable toxicity of either the morpholinos or the
electroporation treatment (data not shown). In addition to other
considerations to be discussed below, an important indication of
specificity of Pax6 morpholino effects was the similarity of the
phenotypes obtained with two different morpholinos targeting
different regions of the Pax6 mRNA molecule.
The observation that Pax6 downregulation and increased cell
death are detected in Pax6-MP[+] optic vesicles 10 h after
electroporation, before lens placode formation, suggests that
Pax6 expression in the optic vesicle is necessary, cell-
autonomously, for its normal development. Abnormal optic
vesicle development was also observed after electroporation of
a dominant-negative Pax6 construct into chick optic vesicle
cells (Reza and Yasuda, 2004a). A requirement for Pax6 in
the neural ectoderm does not appear to be restricted to the
chick embryo, moreover, because Grindley et al. (1995)
observed conspicuous optic vesicle defects prior to the time of
lens placode formation in early Sey/Sey mouse embryos.
Taken together, these results suggest the need to revise the
frequently expressed view that Pax6 is not essential for OV
development (Ashery-Padan and Gruss, 2001; Mathers and
Jamrich, 2000; Philips et al., 2005). Instead, Pax6 seems to be
critical for the transformation of the optic vesicle into a
normal optic cup.
Our results and those of Reza and Yasuda (2004a) also show
that, when the optic vesicle becomes defective as a result of
Pax6 downregulation in the neural epithelium, lens placode
formation does start but becomes arrested at the lens vesicle
stage, despite normal Pax6 expression in the lens epithelium.
There is an apparent contradiction between these results and the
notion that the expression of a normal Pax6 gene in the
prospective lens ectoderm is not only necessary but alsosufficient for lens development (review: Lang, 2004; Ashery-
Padan and Gruss, 2001; Ogino and Yasuda, 2000). The cell-
autonomous need for Pax6 in the lens epithelium has been well
supported by experiments using conditional knockouts and
chimeras in the mouse (Ashery-Padan et al., 2000; Collinson et
al., 2000; Quinn et al., 1996). On the other hand, the notion that
such expression is sufficient for lens development is primarily
based on recombination experiments using tissues isolated from
wild type and small eye (rSey/rSey) rats (Fujiwara et al., 1994),
which showed that lens formation depended upon the genotype
of the surface ectoderm, and was independent of the genotype of
the optic vesicle. Those experiments did not evaluate the degree
of differentiation reached by the lens, however, and it is
therefore unknown whether lens development would have
become arrested in the presence of Sey/Sey optic vesicles, as it
did in the studies by Reza and Yasuda (2004a) and in the
experiments reported here. Therefore, Pax6 expression in the
prospective lens ectoderm, although probably sufficient to
ensure the formation and invagination of a lens placode, may
not by itself ensure further maturation of the lens.
The extensive differences in phenotypic abnormalities
observed when Pax6-MP was electroporated on or before HH
stage 10, as compared to HH stage 11, are not likely to result
from differences in morpholino incorporation, since there were
no significant differences in the area and intensity of
morpholino-associated fluorescence in the OV between: (i) C-
MP and Pax6-MP; (ii) Pax6-MP electroporated at HH stages 10
or 11; or (iii) embryos electroporated at HH stage 11 and fixed
immediately thereafter, compared to embryos electroporated at
stage 10 and fixed when they reached stage 11 (5–7 h later).
Quantitative image analysis, moreover, showed similar changes
in Pax6 immunoreactivity in embryos electroporated with Pax6-
MP at HH stages 10 or 11. Although these measurements rely
on the unverified assumption that morpholino and fluorescein
molecules remain conjugated to each other throughout the
experiment, Pax6-MP fluorescence and Pax6 downregulation
colocalized quite precisely, thus increasing our confidence in
MP fluorescence as an indication of MP localization. The data,
therefore, suggest that the different effects of Pax6-MP at HH
stage 10 and 11 reflect a change in the capacity of the tissue to
respond to Pax6 levels and that the commitment to neural retina
and lens development is fixed after HH St 11, at least relative to
Pax6 levels in the optic vesicle.
A significant proportion of eyes treated with Pax6-MP at or
after HH stage 11 developed abnormalities such as coloboma,
small optic cup and small lens, resembling those in heterozy-
gous small eye mice and rats (Hill et al., 1991; Matsuo et al.,
1993). These abnormalities were accompanied or preceded by
changes in the expression pattern of transcription factors known
to influence early eye morphogenesis, including Pax2, Vax and
Tbx5 (reviewed by Chow and Lang, 2001). In agreement with
reports that Pax2 and Pax6 regulate each other and have
mutually exclusive expression domains (Schwarz et al., 2000),
the marked decrease (or even disappearance) of Pax6
immunofluorescence in the ventral retina was accompanied by
expansion of the Pax2[+] domain. cVax, a transcription factor
normally restricted to and necessary for the development of the
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al., 1999; Schulte et al., 1999), was ectopically expressed in the
dorsal retina domain; this was accompanied by the loss of Tbx5,
a “dorsalizing” transcription factor (Koshiba-Takeuchi et al.,
2000; Leconte et al., 2004). This apparent ventralization of the
retina in response to Pax6 downregulation is complementary to
the dorsalization of the developing eye caused by Pax6
overexpression at optic cup stages (Leconte et al., 2004). Our
loss-of-function approach demonstrates that those effects of
Pax6 are set in motion even earlier, at the OV stage, becoming
critical at St 11–12. This is consistent with transplantation
studies showing that the plasticity of the optic vesicle for
acquiring dorso-ventral characteristics is lost by embryonic
stage 11–12 in the chick (Uemonsa et al., 2002). In addition, all
the molecules expressed in the retina domain and known to
participate in its D–V patterning begin its expression after initial
formation of the optic cup, and thus are delayed relative to that
of Pax6 (Gibson-Brown et al., 1998; Sakuta et al., 2001; Schulte
et al., 1999; Trousse et al., 2001; Zhang and Yang, 2001b).
Taken together, these results support a model in which Pax6
expression may act at the initial steps of the cascade leading to
D–V patterning of the neural retina. A role for non-cell-
autonomous mechanisms must also be considered, however,
because dorso-ventral retina patterning is influenced by
diffusible factors such as sonic hedgehog (Zhang and Yang,
2001b), retinoic acid (Hyatt et al., 1996) and bone morphoge-
netic proteins (Adler and Belecky-Adams, 2002).
Ten hours after electroporation, embryos electroporated with
Pax6-MP at either HH stage 10 or 11 showed a MP[+] region of
similar area and average fluorescence intensity, a 40% decrease
in Pax6 immunofluorescence and a significant increase in the
frequency of TUNEL[+] cells as compared with C-MP
embryos. The increase in TUNEL[+] cells, however, was
significantly higher in embryos electroporated at HH stage 10
than in their stage 11 counterparts. Increases in cell death could
conceivably be caused by trauma associated with electropora-
tion and/or to morpholino toxicity, but this appears unlikely
because there were no detectable increases in TUNEL[+] cells
in OVs electroporated with control morpholinos, or in regions
of the neural tube showing Pax6-MP fluorescence equivalent to
that of the ipsilateral OV. Taken together, therefore, our results
appear to disclose a hitherto unknown, developmental stage-
dependent role of Pax6 in the survival of optic vesicle cells.
While the mechanisms underlying this hypothetical survival-
promoting function remain unknown, it may be relevant that
Pax6 inhibits the transcription of p53 (Stuart et al., 1995) a gene
involved in apoptosis (reviewed in Gomez-Lazaro et al., 2004),
and shares the generalized survival-promoting property of Pax
genes in cancer cells (Maulbecker and Gruss, 1993, Muratovska
et al., 2003; and references therein).
Cell proliferation can be influenced by Pax6 in the CNS
(Simpson and Price, 2002; Warren and Price, 1997; Warren et
al., 1999; see references therein), and is affected in small eye
mice (Philips et al., 2005) as well as after selective Pax6
inactivation in the mouse neural retina (Marquardt et al., 2001).
We did not observe any changes in cell proliferation in embryos
analyzed 10 h after electroporation, when changes in Pax6expression and in cell death were already significant. Similarly,
we did not observe any indications of extrusion from the optic
vesicle of cells exhibiting Pax6-MP fluorescence, equivalent to
the sorting of Pax6(−/−) from Pax6(+/+) cells in chimeric
animals proposed as a possible mechanism of ocular abnor-
malities in small eye mutants (Collinson et al., 2000; Quinn et
al., 1996). These negative results do not conclusively exclude
the possibility that cell proliferation and cell sorting may
contribute to the phenotypic abnormalities caused by morpho-
lino-induced Pax6 downregulation. Nevertheless, our data
suggest that increased cell death and abnormal expression of
several transcription factors are key mechanisms in the genesis
of ocular abnormalities triggered by Pax6 downregulation. Our
results, and those from the literature summarized above, suggest
that normal early eye development requires Pax6 expression
both in the lens ectoderm and in the optic vesicle, and that there
is a critical stage during which Pax6 expression in the optic
vesicle is required not only for optic vesicle development, but
also for lens development.
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